Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 600
Filter
Add more filters

Publication year range
1.
Ecotoxicol Environ Saf ; 210: 111863, 2021 Mar 01.
Article in English | MEDLINE | ID: mdl-33406447

ABSTRACT

BACKGROUND: Experimental and epidemiological studies have linked antibiotics use to gut dysbiosis-mediated risk of chronic metabolic diseases. However, whether adiposity is linked to antibiotic exposure in elderly remains inadequately understood. OBJECTIVE: To investigate the association between internal exposure of antibiotics and adiposity in elderly by using a biomonitoring method. METHODS: We included 990 participants (≥60 years) from the baseline survey of the Cohort of Elderly Health and Environment Controllable Factors in Lu'an city, China, from June to September 2016. Forty-five antibiotics and two metabolites in urine were monitored through liquid chromatography-electrospray tandem mass spectrometry (HPLC-MS/MS). Creatinine-corrected urinary concentrations were used to assess antibiotic exposure levels. Body mass index (BMI), waist circumference (WC) and body fat percentage (BFP) were used as indicators of adiposity. Multiple linear regression and binary logistic regression analyses were used to analyze the association of antibiotic concentrations with obesity-related indices. Subsequently, a gender-stratified analysis was performed. RESULTS: Of the included elderly, 50.7% were defined as having overweight/ obesity, 59.8% as having central preobesity/obesity, and 37.5% as having slightly high/high BFP. Linear regression analysis revealed that a 1-unit increase in the logarithmic transformation of norfloxacin concentrations was related with an increase of 0.29 kg/m2 (95% CI: 0.02-0.04), 0.99 cm (95% CI:0.24-1.75), and 0.69% (95% CI:0.21-1.17) in BMI, WC, and BFP, respectively. Compared with the control group, exposure to doxycycline (tertile 2: odds ratio, 2.06 [95% CI: 1.12-3.76]) and norfloxacin (tertile 2: 2.13 [1.05-4.29]; tertile 3: 2.07 [1.03-4.17]) had BMI-based overweight/obesity risk. Additionally, ciprofloxacin (tertile 2: 2.06 [1.12-3.76]), norfloxacin (tertile 3: 2.95 [1.34-6.49]), and florfenicol (tertile 3: 1.84 [1.07-3.14]) were related to WC-based central preobesity/obesity risk. Norfloxacin (tertile 3: 2.54 [1.23-5.24]) was positively associated with a slightly high/high BFP risk. Gender-stratified analysis demonstrated an increased adiposity risk in women compared with men. CONCLUSIONS: Our research provided an evidence that exposure to specific types of antibiotics (tetracyclines and fluoroquinolones) probably from the food chain contributed to obesity in elderly. Prospective cohort studies with larger sample size are warrented to explore the causation.


Subject(s)
Anti-Bacterial Agents/urine , Obesity/epidemiology , Adiposity , Aged , Biological Monitoring , Body Mass Index , China/epidemiology , Cohort Studies , Female , Humans , Independent Living , Male , Middle Aged , Obesity/urine , Odds Ratio , Risk Factors , Waist Circumference
2.
Molecules ; 26(6)2021 Mar 23.
Article in English | MEDLINE | ID: mdl-33806905

ABSTRACT

In this work, previously synthesized and characterized core-shell silica nanoparticles (FCSNP) functionalized with immobilized molecular bait, Cibacron blue, and a porous polymeric bis-acrylamide shell were incubated with pooled urine samples from adult women or men with normal weight, overweight or obesity for the isolation of potential biomarkers. A total of 30 individuals (15 woman and 15 men) were included. FCSNP allowed the capture of a variety of low molecular weight (LMW) proteins as evidenced by mass spectrometry (MS) and the exclusion of high molecular weight (HMW) proteins (>34 kDa) as demonstrated by SDS-PAGE and 2D SDS-PAGE. A total of 36 proteins were successfully identified by MS and homology database searching against the Homo sapiens subset of the Swiss-Prot database. Identified proteins were grouped into different clusters according to their abundance patterns. Four proteins were found only in women and five only in men, whereas 27 proteins were in urine from both genders with different abundance patterns. Based on these results, this new approach represents an alternative tool for isolation and identification of urinary biomarkers.


Subject(s)
Obesity/urine , Proteinuria/urine , Proteomics , Adult , Biomarkers/urine , Female , Humans , Male , Middle Aged
3.
Molecules ; 26(5)2021 Mar 05.
Article in English | MEDLINE | ID: mdl-33807567

ABSTRACT

Catecholamines are physiological regulators of carbohydrate and lipid metabolism during stress, but their chronic influence on metabolic changes in obese patients is still not clarified. The present study aimed to establish the associations between the catecholamine metabolites and metabolic syndrome (MS) components in obese women as well as to reveal the possible hidden subgroups of patients through hierarchical cluster analysis and principal component analysis. The 24-h urine excretion of metanephrine and normetanephrine was investigated in 150 obese women (54 non diabetic without MS, 70 non-diabetic with MS and 26 with type 2 diabetes). The interrelations between carbohydrate disturbances, metabolic syndrome components and stress response hormones were studied. Exploratory data analysis was used to determine different patterns of similarities among the patients. Normetanephrine concentrations were significantly increased in postmenopausal patients and in women with morbid obesity, type 2 diabetes, and hypertension but not with prediabetes. Both metanephrine and normetanephrine levels were positively associated with glucose concentrations one hour after glucose load irrespectively of the insulin levels. The exploratory data analysis showed different risk subgroups among the investigated obese women. The development of predictive tools that include not only traditional metabolic risk factors, but also markers of stress response systems might help for specific risk estimation in obesity patients.


Subject(s)
Metanephrine/urine , Multivariate Analysis , Normetanephrine/urine , Obesity/urine , Adolescent , Adult , Aged , Biomarkers/urine , Cluster Analysis , Diabetes Mellitus, Type 2/urine , Female , Humans , Metabolic Syndrome/urine , Middle Aged , Obesity/complications , Obesity/metabolism , Waist Circumference
4.
Mo Med ; 118(2): 113-115, 2021.
Article in English | MEDLINE | ID: mdl-33840847

ABSTRACT

The factors contributing to increased morbidity and mortality in SARS-CoV-2 infection are diverse, and include diabetes, obesity, Chronic Obstructive Pulmonary Disease (COPD), advanced age, and male sex. Although there is no obvious connection between these, they do have one common denominator-they all have a tendency towards lower urine pH, which may indicate a lower-than-normal tissue pH. Furthermore, it has been shown that lower pH has two important negative influences: 1) it enhances viral fusion via the endosomal route, thereby facilitating viral multiplication; and 2) it facilitates increased production of inflammatory cytokines, thereby exacerbating the cytokine storm. This paper discusses published literature on lower tissue/interstitial pH in those diseases/co-morbidities that are known risk factors of severe COVID-19, and hypothesize that small doses of baking soda could be a simple, cost-effective, and rapid method of reducing both morbidity and mortality in COVID-19 patients.


Subject(s)
Acidosis/metabolism , COVID-19/metabolism , Cytokines/metabolism , Diabetes Mellitus/metabolism , Obesity/metabolism , Pulmonary Disease, Chronic Obstructive/metabolism , Virus Internalization , Acidosis/drug therapy , Acidosis/urine , Age Factors , COVID-19/epidemiology , COVID-19/mortality , COVID-19/physiopathology , Cytokine Release Syndrome , Diabetes Mellitus/epidemiology , Diabetes Mellitus/urine , Early Medical Intervention , Humans , Hydrogen-Ion Concentration , Obesity/epidemiology , Obesity/urine , Pulmonary Disease, Chronic Obstructive/epidemiology , Pulmonary Disease, Chronic Obstructive/urine , Risk Factors , SARS-CoV-2 , Severity of Illness Index , Sex Factors , Sodium Bicarbonate/therapeutic use , Urine/chemistry
5.
Mol Biol Rep ; 47(6): 4109-4116, 2020 Jun.
Article in English | MEDLINE | ID: mdl-32424522

ABSTRACT

BACKGROUND: The incidence of obesity-related asthma has shown a remarkable increase. OBJECTIVES: We aimed to explore the role of heat shock protein 72 (Hsp72) and receptor for advanced glycation end products (RAGE) axis with its downstream signaling in the pathogenesis of obesity-related asthma. METHODS: We enrolled a total of 55 subjects and divided them into three groups. Groups I and II included healthy, normal weight (n = 15) and obese (n = 15) subjects, respectively. Twenty-five obese asthmatics (group III) were subdivided into group IIIa (10 patients with mild to moderate asthma) and group IIIb (15 patients with severe asthma). High mobility group box 1 (HMGB1), interleukin 8 (IL-8), monocyte chemoattractant protein 1 (MCP-1), extracellular signal-regulated protein kinases 1 and 2 (ERK1/2), and urinary Hsp72 were immunoassayed. Hydrogen peroxide (H2O2) and free fatty acids (FFAs) levels were photometrically measured. RAGE mRNA expression was relatively quantified by real-time PCR. RESULTS: We found significant elevations of serum HMGB1, IL-8, MCP1, ERK1/2, FFAs, and H2O2 levels as well as urinary Hsp72 levels in obese subjects compared to healthy control. These were more evident in patients with severe asthma (group IIIb). Multivariate regression analysis identified Hsp72 and ERK1/2 as independent predictors of bronchial asthma severity. Receiver operating characteristic (ROC) curve analysis revealed that areas under the curve (AUC) for Hsp72 and ERK1/2 were 0.991 and 0.981, respectively, which denotes a strong predictive value for identifying the severity of bronchial asthma in obese patients. CONCLUSION: The current study highlights the role of Hsp72 and HMGB1/RAGE/ERK1/2 signaling cascade in the pathogenesis of bronchial asthma and its link to obesity, which could be reflected on monitoring, severity grading, and management of this disease.


Subject(s)
Antigens, Neoplasm/blood , Asthma/blood , HMGB1 Protein/blood , Heat-Shock Proteins/blood , MAP Kinase Signaling System , Mitogen-Activated Protein Kinases/blood , Molecular Chaperones/blood , Obesity/blood , Adult , Asthma/immunology , Asthma/urine , Case-Control Studies , Chemokine CCL2/blood , Fatty Acids, Nonesterified/blood , Fatty Acids, Nonesterified/metabolism , Female , HMGB1 Protein/urine , Heat-Shock Proteins/urine , Humans , Hydrogen Peroxide/blood , Hydrogen Peroxide/metabolism , Interleukin-8/blood , Male , Middle Aged , Molecular Chaperones/urine , Obesity/immunology , Obesity/urine , Receptor Cross-Talk
6.
Ecotoxicol Environ Saf ; 201: 110749, 2020 Sep 15.
Article in English | MEDLINE | ID: mdl-32505048

ABSTRACT

BACKGROUND: Few epidemiological studies on the correlation between phthalate exposure and elderly obesity in China are available. The purpose of the present study is to assess phthalate exposure levels and explore the connections between exposure to phthalates and obesity using a sample of Chinese community-dwelling elderly individuals. METHODS: Data were acquired from the baseline survey of the Cohort of Health of Elderly and Controllable Factors of Environment, which was established in Lu'an, Anhui province, China, from June to September in 2016. Urine samples were obtained to analyze the concentrations of seven phthalate metabolites, utilizing a high-performance liquid chromatography-tandem mass spectrometry method. General obesity was determined based on body mass index, and abdominal obesity based on waist circumference. Binary logistic regression models were utilized to analyze the associations of creatinine-corrected phthalate metabolite concentrations (categorized into quartiles) with general and abdominal obesity in elderly people. Moreover, a stratified analysis was performed to explore the difference between genders. RESULTS: Of 942 elderly individuals, 52.9% were defined as generally obese and 75.5% as abdominally obese. The detection rates of seven phthalate metabolites ranged from 90.07% to 99.80%. The highest median concentration was 44.08 µg/l (for MBP), and the lowest was 0.55 µg/l (for MEHP). The level of exposure to LMW(low-molecular-weight) PAEs is higher than that to HMW(high-molecular-weight) PAEs. After adjustment for confounding variables, we found a significant association between urinary MEOHP (mono-2-ethyl-5-oxohexyl phthalate), MEHP (mono-2-ethylhexyl phthalate), MBP (mono-n-butyl phthalate), MEP (mono-ethyl phthalate), and MMP (mono-methyl phthalate) levels and general obesity. MBP levels were also correlated with abdominal obesity. When stratified by gender, higher urinary levels of MEOHP, MBP, MEP, and MMP were associated with general obesity in males, whereas MBP and MMP levels were eminently correlated with general obesity in females. Higher urinary MBP levels were associated with increased abdominal obesity rates in males, but not in females. CONCLUSIONS: In conclusion, higher phthalate metabolite concentrations were correlated with obesity in the elderly. Moreover, a gender difference was observed in these associations.


Subject(s)
Environmental Exposure/statistics & numerical data , Environmental Pollutants/urine , Obesity/epidemiology , Phthalic Acids/urine , Aged , Body Mass Index , China/epidemiology , Cohort Studies , Environmental Exposure/analysis , Environmental Pollutants/chemistry , Female , Humans , Male , Obesity/urine , Phthalic Acids/chemistry , Sex Factors
7.
Am J Physiol Renal Physiol ; 317(7): F12-F22, 2019 07 01.
Article in English | MEDLINE | ID: mdl-31042059

ABSTRACT

Metabolic syndrome (MetS) is associated with nutrient surplus and kidney hyperfiltration, accelerating chronic renal failure. The potential involvement of podocyte damage in early MetS remains unclear. Mitochondrial dysfunction is an important determinant of renal damage, but whether it contributes to MetS-related podocyte injury remains unknown. Domestic pigs were studied after 16 wk of diet-induced MetS, MetS treated with the mitochondria-targeted peptide elamipretide (ELAM; 0.1 mg·kg-1·day-1 sc) for the last month of diet, and lean controls (n = 6 pigs/group). Glomerular filtration rate (GFR) and renal blood flow (RBF) were measured using multidetector computed tomography, and podocyte and mitochondrial injury were measured by light and electron microscopy. Urinary levels of podocyte-derived extracellular vesicles (pEVs; nephrin positive/podocalyxin positive) were characterized by flow cytometry. Body weight, blood pressure, RBF, and GFR were elevated in MetS. Glomerular size and glomerular injury score were also elevated in MetS and decreased after ELAM treatment. Evidence of podocyte injury, impaired podocyte mitochondria, and foot process width were all increased in MetS but restored with ELAM. The urinary concentration of pEVs was elevated in MetS pigs and directly correlated with renal dysfunction, glomerular injury, and fibrosis and inversely correlated with glomerular nephrin expression. Additionally, pEV numbers were elevated in the urine of obese compared with lean human patients. Early MetS induces podocyte injury and mitochondrial damage, which can be blunted by mitoprotection. Urinary pEVs reflecting podocyte injury might represent early markers of MetS-related kidney disease and a novel therapeutic target.


Subject(s)
Extracellular Vesicles/ultrastructure , Metabolic Syndrome/pathology , Mitochondria/physiology , Podocytes/ultrastructure , Animals , Diet , Diet, High-Fat , Female , Fructose/administration & dosage , Glomerular Filtration Rate , Humans , Kidney/blood supply , Kidney/pathology , Kidney/physiopathology , Kidney Glomerulus/drug effects , Kidney Glomerulus/pathology , Metabolic Syndrome/drug therapy , Metabolic Syndrome/etiology , Mitochondria/ultrastructure , Obesity/urine , Oligopeptides/therapeutic use , Podocytes/drug effects , Renal Circulation , Sus scrofa , Urine
8.
Nephrology (Carlton) ; 24(11): 1131-1141, 2019 Nov.
Article in English | MEDLINE | ID: mdl-30582257

ABSTRACT

AIM: Metabolic acidosis occurs due to insufficient urinary ammonium excretion as chronic kidney disease (CKD) advances. Because obese subjects tend to have excessive consumption of protein and sodium chloride, they are prone to chronic acid loading and may therefore be predisposed to acid-induced kidney injury. We investigated the involvement of obesity in ammoniagenesis within damaged kidneys. METHODS: In the clinical study, urinary ammonium excretion was compared between 13 normal-weight and 15 overweight/obese CKD outpatients whose creatinine clearance was higher than 25 mL/min. For animal experiments, NH4 Cl was loaded to KKAy/TaJcl (KKAy), a metabolic syndrome model, and control BALB/c mice for 20 weeks. Kidney injury was evaluated through histological analysis and the expression of proinflammatory markers. RESULTS: Urinary ammonium excretion was lower in overweight/obese patients than in normal-weight patients, while intakes of protein and sodium chloride were higher in overweight/obese patients, implying that subclinical metabolic acidosis occurs in overweight/obese patients. The increase in urinary ammonium excretion induced by NH4 Cl loading was attenuated in KKAy mice after 16 weeks, whereas the increase was maintained in BALB/c mice throughout the study period. Histological study and real-time polymerase chain reaction analysis showed proximal tubular injury and enhanced expression levels of neutrophil gelatinase-associated lipocalin (NGAL) protein and messenger RNA, respectively, in KKAy mice but not in BALB/c mice. Finally, urinary NGAL concentration was higher in overweight/obese patients than in normal-weight patients in the early stage of CKD. CONCLUSION: Obesity could facilitate the induction of subclinical metabolic acidosis and acid accumulation in the kidney, which may potentially exacerbate kidney injury in CKD patients.


Subject(s)
Ammonia/urine , Kidney Tubules/pathology , Obesity/urine , Overweight/urine , Renal Insufficiency, Chronic/urine , Acidosis/etiology , Acids/urine , Aged , Animals , Female , Humans , Lipocalin-2/urine , Male , Mice , Mice, Inbred BALB C , Middle Aged
9.
J Clin Nurs ; 28(9-10): 1808-1818, 2019 May.
Article in English | MEDLINE | ID: mdl-30667588

ABSTRACT

AIMS AND OBJECTIVES: To determine whether a weight management intervention (WMI) plus cardiac rehabilitation (CR) compared to CR alone improves outcomes for overweight and obese cardiac revascularisation patients. BACKGROUND: Despite participating in cardiac rehabilitation (CR), few cardiac patients lose enough weight to achieve clinically significant cardiovascular disease risk reduction. DESIGN: A randomised controlled design was used with measurements at baseline, 4 and 6 months, guided by the CONSORT checklist, see Supporting Information File S1. Adults who had undergone either coronary artery bypass surgery (CABS) or percutaneous coronary intervention (PCI) and participated in a rural CR programmes were recruited. Subjects were randomised to a 12-week telehealth WMI or control group. The primary outcome was weight loss. Secondary outcomes included physical activity, patient activation, perceived self-efficacy and use of weight management behaviours. RESULTS: A total of 43 subjects participated, with a mean age of 63 (±9.3) years. The WMI group had significantly more weight loss averaged across the 4 and 6 months of 13.8 (±2.8) pounds compared to the control group [mean = 7.8 (±2.2) pounds]. There were no significant differences in physical activity (activity counts or daily minutes in moderate or more intense activity). The WMI group had significantly higher levels of patient activation. They also had significantly higher total scores on the Diet and Exercise Self-Management survey, and subscales that included self-efficacy for specific eating habits and managing diet behaviour. CONCLUSIONS: Findings demonstrated the usefulness and feasibility of using telehealth delivery of the WMI for cardiac rehabilitation participants in rural communities to improve weight management outcomes. RELEVANCE TO PRACTICE: Study findings underscore the opportunity to further improve weight loss of overweight and obese cardiac participants using a weight management intervention to augment CR participation.


Subject(s)
Cardiac Rehabilitation/methods , Obesity/urine , Telemedicine/methods , Weight Loss , Aged , Analysis of Variance , Exercise , Female , Humans , Male , Middle Aged , Rural Population/statistics & numerical data , Self Efficacy , Surveys and Questionnaires
10.
Int J Mol Sci ; 20(19)2019 Oct 03.
Article in English | MEDLINE | ID: mdl-31623319

ABSTRACT

Metabolic dysfunction associated with obesity threatens to inundate health care resources by increasing the incidences of obesity-related diseases. The aim of the present study was to investigate the changes in the urinary proteome of 18 individuals classified into metabolically healthy obese (MHO) and metabolically unhealthy obese (MUHO) patients. Proteome analysis was performed using the two-dimensional difference in gel electrophoresis (2D-DIGE) coupled with mass spectrometry (MS). Upon analysis, a total of 54 proteins were found to be affected with ≥1.5-fold change (ANOVA, p ≤ 0.05), of which 44 proteins were upregulated and 10 proteins were downregulated. These differentially abundant proteins were related to nuclear factor κB (NF-κB) and p38 mitogen-activated protein (MAP) kinase pathways and were involved in cellular compromise, inflammatory response, and cancer. Proteins involved in inflammation (fibrinogen alpha (FIBA), serotransferrin (TRFE, and kininogen-1 (KNG1)) and insulin resistance (ADP-ribosylation factor (ARF)-like protein 15 (ARL15) and retinol-binding protein 4 (RET4)) were found to be significantly increased in the urine samples of MUHO compared to MHO patients. Investigating the effects of obesity on urinary proteins can help in developing efficient diagnostic procedures for early detection and prevention of obesity-related complications.


Subject(s)
Obesity/urine , Proteinuria/urine , Proteome , Proteomics , Adult , Biomarkers , Female , Health Status , Humans , Male , Obesity/complications , Protein Interaction Mapping , Proteinuria/etiology , Proteomics/methods
11.
Int J Environ Health Res ; 29(1): 94-106, 2019 Feb.
Article in English | MEDLINE | ID: mdl-30203985

ABSTRACT

In this study, the association of exposure to Bisphenol A (BPA) with obesity and cardiometabolic risk factors was investigated on 132 children and adolescents aged 6-18 years living in Isfahan, Iran. Potential contributors to BPA exposure were assessed by a questionnaire. Total BPA was detected in urine samples of all participants without significant difference in boys and girls. The mean body mass index (BMI) and waist circumference (WC) increased significantly across the BPA tertiles (p for trend = < 0.001). Similar trend was documented for systolic blood pressure (SBP) and diastolic blood pressure (DBP) as well as fasting blood sugar. The risk of obesity was 12.48 times higher in participants in the third tertile of BPA than in others (95% CI: 3.36-46.39, p < 0.001). The current study showed significant association between BPA exposure with obesity and some cardiometabolic risk factors in children and adolescents, however, further longitudinal studies are necessary to evaluate the clinical effects of this finding. Abbreviations: BMI: Body Mass Index; BPA: Bisphenol A; BSTFA: N, O-Bistrifluoroacetamide; CDC: Centers for Disease Control and Prevention; CI: Circumference Interval; DBP: Diastolic Blood Pressure; DLLME: Dispersive liquid-liquid microextraction method; FBS: Fasting Blood Glucose; HDL: high-density lipoprotein cholesterol were; LDL: low-density lipoprotein cholesterol; OR: Odd Ratio; PA: Physical Activity; SBP: Systolic Blood Pressure; TC: total cholesterol; TG: triglycerides; WC: Waist Circumference.


Subject(s)
Benzhydryl Compounds/urine , Cardiovascular Diseases/epidemiology , Environmental Pollutants/urine , Obesity/epidemiology , Obesity/urine , Phenols/urine , Adolescent , Child , Environmental Monitoring , Female , Humans , Iran , Male , Risk Factors
12.
Prostate ; 78(1): 17-24, 2018 Jan.
Article in English | MEDLINE | ID: mdl-29080225

ABSTRACT

PURPOSE: Benign prostatic hyperplasia (BPH) is strongly associated with obesity and prostatic tissue inflammation, but the molecular underpinning of this relationship is not known. Here, we examined the association between urine levels of chemokines/adipokines with histological markers of prostate inflammation, obesity, and lower urinary tract symptoms LUTS in BPH patients. METHODS: Frozen urine specimens from 207 BPH/LUTS patients enrolled in Nashville Men's Health Study were sent for blinded analysis of 11 analytes, namely sIL-1RA, CXC chemokines (CXCL-1, CXCL-8, CXCL-10), CC chemokines (CCL2, CCL3, CCL5), PDGF-BB, interleukins IL-6, IL-17, and sCD40L using Luminex™ xMAP® technology. After adjusting for age and medication use, the urine levels of analytes were correlated with the scales of obesity, prostate inflammation grade, extent, and markers of lymphocytic infiltration (CD3 and CD20) using linear regression. RESULTS: sIL-1RA levels were significantly raised with higher BMI, waist circumference and waist-hip ratio in BPH patients after correction for multiple testing (P = 0.02). Men with greater overall extent of inflammatory infiltrates and maximal CD3 infiltration were marginally associated with CXCL-10 (P = 0.054) and CCL5 (P = 0.054), respectively. CCL3 in 15 patients with moderate to severe grade inflammation was marginally associated with maximal CD20 infiltration (P = 0.09), whereas CCL3 was undetectable in men with mild prostate tissue inflammation. There was marginal association of sCD40L with AUA-SI scores (P = 0.07). CONCLUSIONS: Strong association of sIL-1RA in urine with greater body size supports it as a major molecular correlate of obesity in the urine of BPH patients. Increased urine levels of CXCL-10, CCL5, and CCL3 were marginally associated with the scores for prostate tissue inflammation and lymphocytic infiltration. Overall, elevated urinary chemokines support that BPH is a metabolic disorder and suggest a molecular link between BPH/LUTS and prostatic inflammation.


Subject(s)
Chemokines/urine , Cytokines/urine , Obesity/urine , Prostatic Hyperplasia/urine , Prostatic Neoplasms/urine , Prostatitis/urine , Aged , Body Mass Index , Humans , Male , Middle Aged , Obesity/pathology , Prostatic Hyperplasia/pathology , Prostatic Neoplasms/pathology , Prostatitis/pathology , Urinalysis
13.
Toxicol Appl Pharmacol ; 350: 11-20, 2018 07 01.
Article in English | MEDLINE | ID: mdl-29723618

ABSTRACT

Our recent study found that high urinary total arsenic levels were associated with renal cell carcinoma (RCC). Recent studies demonstrated that low circulating adiponectin was related to RCC. The aim of the present study was to explore the relationship between adiponectin gene (ADIPOQ) polymorphisms and RCC and investigate whether individuals with an ADIPOQ risk genotype, obesity, and high urinary total arsenic levels have a modified odds ratio (OR) of RCC. A total of 389 RCC patients and 389 age- and sex-matched controls were recruited between November 2006 and December 2012 in Taiwan. Image-guided biopsy or surgical resection of renal tumors was performed to pathologically verify RCC. Genomic DNA was used to examine the genotypes of the ADIPOQ rs182052, ADIPOQ rs2241766, ADIPOQ rs1501299, and ADIPOQ rs1063539 SNPs by PCR-RFLP. HPLC-HG-AAS was used to measure the concentrations of urinary arsenic species. Participants with the ADIPOQ rs182052 G/A+A/A genotype had a significantly higher OR of RCC compared with those with the ADIPOQ rs182052 G/G genotype. The OR (95% confidence interval [CI]) was 1.70 (1.23-2.36). The OR of RCC for the combined effect of high urinary total arsenic levels and obesity, which was dose-dependent, in individuals with the ADIPOQ rs182052 G/A+A/A genotype was 9.33 (3.85-22.62). The present study found significant combined effects of obesity and the ADIPOQ rs182052 G/A+A/A genotype on the arsenic-related risk of RCC in a population with low arsenic exposure. Arsenic exposure, obesity, and the ADIPOQ rs182052 polymorphism could be predictors of a higher OR of RCC.


Subject(s)
Adiponectin/genetics , Arsenic , Carcinoma, Renal Cell/genetics , Kidney Neoplasms/genetics , Obesity/genetics , Polymorphism, Single Nucleotide/genetics , Arsenic/urine , Biomarkers, Tumor/urine , Carcinoma, Renal Cell/epidemiology , Carcinoma, Renal Cell/urine , Case-Control Studies , Female , Genetic Predisposition to Disease/epidemiology , Genetic Predisposition to Disease/genetics , Humans , Kidney Neoplasms/epidemiology , Kidney Neoplasms/urine , Male , Middle Aged , Obesity/epidemiology , Obesity/urine , Taiwan/epidemiology
14.
Am J Nephrol ; 47(5): 283-291, 2018.
Article in English | MEDLINE | ID: mdl-29779026

ABSTRACT

BACKGROUND: Extracellular vesicles (EVs) enclose mRNA derived from their cell of origin and are considered a source of potential biomarkers. We examined urinary EV mRNA from individuals with diabetic kidney disease (DKD), chronic kidney disease, type 2 diabetes (T2DM), and obese and healthy controls to determine if such biomarkers had the potential to classify kidney disease and predict patients at higher risk of renal function decline. METHODS: A total of 242 participants enrolled in this study. Urinary EV mRNA from all subjects were isolated by a filter-based platform, and the expression of 8 target genes were determined by quantitative polymerase chain reaction (qPCR). Changes in estimated glomerular filtration rate (eGFR) in 161 T2DM patients were evaluated for 2 consecutive years and compared with EV RNA profiles at baseline. RESULTS: We observe that mild and severe DKD groups show a significant 3.2- and -4.4-fold increase in UMOD compared to healthy controls and expression increases linearly from healthy, diabetic, and DKD subjects. UMOD expression is significantly correlated to albumin creatinine ratio (ACR), eGFR, and HbA1c. Using linear discriminant analyses with mRNA from severe DKD and T2DM as training data, a multi-gene signature classified DKD and -non-DKD with a sensitivity of 93% and specificity of 73% with area under the receiver operating characteristic (ROC) curve (AUC) = 0.90. Although 6% of T2DM were determined to have a > 80% posterior probability of developing DKD based on this mRNA profile, eGFR changes observed within the 2-year follow-up did not reveal a decline in kidney function. CONCLUSION: Urinary EV UMOD mRNA levels are progressively elevated from T2DM to DKD groups and correlate with widely used eGFR and ACR diagnostic criteria. An EV mRNA signature could identify DKD with greater than 90% sensitivity and 70% specificity.


Subject(s)
Diabetes Mellitus, Type 2/urine , Diabetic Nephropathies/diagnosis , Kidney/physiopathology , RNA, Messenger/urine , Uromodulin/urine , Adult , Aged , Biomarkers/urine , Cell-Free Nucleic Acids/urine , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/physiopathology , Diabetic Nephropathies/physiopathology , Diabetic Nephropathies/urine , Extracellular Vesicles/genetics , Female , Glomerular Filtration Rate , Healthy Volunteers , Humans , Male , Middle Aged , Obesity/urine , Predictive Value of Tests , Prognosis , RNA, Messenger/isolation & purification , ROC Curve , Renal Insufficiency, Chronic/urine , Risk Assessment/methods , Severity of Illness Index , Uromodulin/genetics
15.
Diabetes Obes Metab ; 20(8): 1878-1884, 2018 08.
Article in English | MEDLINE | ID: mdl-29577550

ABSTRACT

AIMS: Methionine aminopeptidase 2 (MetAP2) inhibition has been shown to result in significant weight loss and improved glucose control. This Phase 1 clinical trial assessed the safety and tolerability, pharmacokinetics and preliminary efficacy of a novel MetAP2 inhibitor, ZGN-1061. METHODS: This clinical trial included a single ascending dose (SAD) phase in healthy subjects (BMI, 23 to <30 kg/m2 ) and a multiple ascending dose (MAD) phase in otherwise healthy subjects (BMI, 27 to 40 kg/m2 ). SAD phase doses, administered subcutaneously (SC), were 0.2, 0.6, 1.2, 2.4, 3.6 and 4.8 mg and the MAD phase evaluated doses of 0.2, 0.6 and 1.8 mg twice weekly SC for 4 weeks. RESULTS: The SAD phase included 39 subjects (ZGN-1061, N = 28; placebo, N = 11); 90% were male and BMI was 26.4 kg/m2 . ZGN-1061 was well tolerated across all doses, with the most frequent adverse events being mild headache and procedural-related irritation. There were no severe or serious adverse events. All doses of ZGN-1061 were rapidly absorbed and cleared, resulting in short duration of exposure that is anticipated to minimize potential off-drug target risks. The MAD phase included 29 subjects (ZGN-1061, N = 22; placebo, N = 7); 76% were male and BMI was 33.5 kg/m2 . Safety observations were consistent with SAD findings. Efficacy measures in the MAD phase indicated trends for weight change (-1.5 kg total ZGN-1061 vs -0.2 kg placebo) and other biomarker changes. CONCLUSIONS: ZGN-1061 was well tolerated with no safety signals in all doses tested. In addition, the desired pharmacokinetic profile and preliminary efficacy observations with ZGN-1061 support evaluation in larger and longer clinical trials.


Subject(s)
Aminopeptidases/antagonists & inhibitors , Anti-Obesity Agents/administration & dosage , Azetidines/administration & dosage , Drugs, Investigational/administration & dosage , Glycoproteins/antagonists & inhibitors , Morpholines/administration & dosage , Obesity/drug therapy , Overweight/drug therapy , Protease Inhibitors/administration & dosage , Absorption, Physiological , Adult , Aminopeptidases/metabolism , Anti-Obesity Agents/adverse effects , Anti-Obesity Agents/pharmacokinetics , Azetidines/adverse effects , Azetidines/pharmacokinetics , Biomarkers/blood , Biomarkers/urine , Body Mass Index , Cohort Studies , Dose-Response Relationship, Drug , Double-Blind Method , Drugs, Investigational/adverse effects , Drugs, Investigational/pharmacokinetics , Female , Follow-Up Studies , Glycoproteins/metabolism , Half-Life , Humans , Injections, Subcutaneous , Male , Metabolic Clearance Rate , Methionyl Aminopeptidases , Morpholines/adverse effects , Morpholines/pharmacokinetics , Obesity/blood , Obesity/metabolism , Obesity/urine , Overweight/blood , Overweight/metabolism , Overweight/urine , Protease Inhibitors/adverse effects , Protease Inhibitors/pharmacokinetics , Weight Loss/drug effects , Young Adult
16.
Br J Clin Pharmacol ; 84(8): 1738-1747, 2018 08.
Article in English | MEDLINE | ID: mdl-29618168

ABSTRACT

AIMS: To test the in vivo activity of Cytochrome P450 (CYP) 2E1 in obese children vs. nonobese children, aged 11-18 years. Secondly, whether the activity of CYP2E1 in these patients is associated with NALFD, diabetes or hyperlipidaemia. METHODS: Seventy children were divided into groups by body mass index (BMI) standard deviation score (SDS). All children received 250 mg oral chlorzoxazone (CLZ) as probe for CYP2E1 activity. Thirteen blood samples and 20-h urine samples were collected per participant. RESULTS: Obese children had an increased oral clearance and distribution of CLZ, indicating increased CYP2E1 activity, similar to obese adults. The mean AUC0-∞ value of CLZ was decreased by 46% in obese children compared to nonobese children. The F was was increased twofold in obese children compared to nonobese children, P < 0.0001. Diabetic biomarkers were significantly increased in obese children, while fasting blood glucose and Hba1c levels were nonsignificant between groups. Liver fat content was not associated with CLZ Cl. CONCLUSION: Oral clearance of CLZ was increased two-fold in obese children vs. nonobese children aged 11-18 years. This indicates an increased CYP2E1 activity of clinical importance, and dose adjustment should be considered for CLZ.


Subject(s)
Chlorzoxazone/pharmacokinetics , Cytochrome P-450 CYP2E1/metabolism , Obesity/metabolism , Administration, Oral , Adolescent , Area Under Curve , Body Mass Index , Child , Chlorzoxazone/administration & dosage , Diabetes Mellitus , Dose-Response Relationship, Drug , Fatty Liver , Female , Humans , Hydroxylation , Male , Metabolic Clearance Rate/physiology , Obesity/blood , Obesity/physiopathology , Obesity/urine
17.
Toxicol Pathol ; 46(7): 777-798, 2018 10.
Article in English | MEDLINE | ID: mdl-30343647

ABSTRACT

The obese rodent serves as an indispensable tool for proof-of-concept efficacy and mode-of-action pharmacology studies. Yet the utility of this disease model as an adjunct to the conventional healthy animal in the nonclinical safety evaluation of anti-obesity pharmacotherapies has not been elucidated. Regulatory authorities have recommended employing disease models in toxicology studies when necessary. Our study investigated standard and exploratory toxicology parameters in the high-fat diet (HFD)-induced obese, polygenic Sprague-Dawley rat model in comparison to chow diet (CD)-fed controls. We sought to establish feasibility of the model for safety testing and relevance to human obesity pathophysiology. We report that both sexes fed a 45% kcal HFD for 29 weeks developed obesity and metabolic derangements that mimics to a certain extent, common human obesity. Minor clinical pathologies were observed in both sexes and considered related to CD versus HFD differences. Histopathologically, both sexes exhibited mild obesity-associated findings in brown and subcutaneous white fat, bone, kidneys, liver, lung, pancreas, salivary parotid glands, and skeletal muscle. We conclude that chronic HFD feeding in both sexes led to the development of an obese but otherwise healthy rat. Therefore, the diet-induced obese Sprague-Dawley rat may serve as a suitable model for evaluating toxicity findings encountered with anti-obesity compounds.


Subject(s)
Diet, High-Fat/adverse effects , Disease Models, Animal , Obesity/etiology , Animals , Anti-Obesity Agents/toxicity , Biomarkers/blood , Biomarkers/urine , Body Weight/physiology , Drug Evaluation, Preclinical , Estrous Cycle/physiology , Female , Male , Obesity/blood , Obesity/physiopathology , Obesity/urine , Organ Size/physiology , Organ Specificity/physiology , Proof of Concept Study , Rats, Sprague-Dawley
18.
Biol Pharm Bull ; 41(10): 1581-1585, 2018.
Article in English | MEDLINE | ID: mdl-30270327

ABSTRACT

The objective of this study was to confirm the effect of maternal genistein exposure on body weight of male offspring and the metabolic alterations associated with maternal genistein-induced obesity. Pregnant female Sprague-Dawley (SD) rats were supplemented with 300 mg/kg diet of genistein (GEN) or no genistein (CON) throughout pregnancy and lactation. The growth of male offspring was investigated until 12 week age and the mechanism of obesity was studied using metabonomics by ultra performance liquid chromatography and quadrupole time-of-flight (UPLC Q-TOF) MS with electrospray ionization in positive ESI mode (ESI+). Compared with the CON group, body weight, fat pad and food intake of male offspring in GEN group were increased significantly at the age of weeks 10 to 12 (p<0.05). Ten urine principal metabolites contributing to the clusters were identified, including increased 8-Isoprostaglandin F2a, and decreased L-Proline, Betaine, L-Acetylcarnitine, Norsalsolinol, Indoleacrylic acid, L-Tryptophan, Lysophosphatidylcholines (LysoPC) (20 : 4), Lysophosphatidylethanolamines (LysoPE) (18 : 1) and LysoPC (O-18 : 0). Our results confirmed weight-increasing effects of maternal genistein exposure, accompanied by favorable changes in metabolites in the male offspring' urine. Therefore, this research enables us to better understand obesity and predict risk of obesity-related disease by studying metabolites present in the urine.


Subject(s)
Genistein/adverse effects , Lactation , Maternal Nutritional Physiological Phenomena , Metabolome , Obesity/etiology , Phytoestrogens/adverse effects , Prenatal Exposure Delayed Effects , Adipose Tissue/metabolism , Animals , Biomarkers/metabolism , Chromatography, High Pressure Liquid , Diet , Dietary Supplements , Eating , Female , Male , Metabolomics/methods , Obesity/urine , Pregnancy , Rats, Sprague-Dawley , Spectrometry, Mass, Electrospray Ionization , Weight Gain
19.
J Obstet Gynaecol Res ; 44(3): 384-389, 2018 Mar.
Article in English | MEDLINE | ID: mdl-29239056

ABSTRACT

AIM: We examined body mass index (BMI) and gestational weight gain (GWG) patterns of pregnant women and investigated the impact of these factors on the urinary albumin-creatinine ratio (ACR) during pregnancy. METHODS: The data of 163 women whose basal BMI and ACR were measured during the first trimester were used in this study. Body weight alone between 12-16 weeks and body weight together with ACR after 37 weeks of gestation were measured. RESULTS: Overall, 46% of women were overweight or obese, 60.7% had excessive weight gain and 16.6% had inadequate weight gain. Only 22.7% of women gained weight within the recommended range. There was no difference in weight gain patterns with respect to BMI. ACR during the third trimester was significantly higher than during the first trimester (7.08 [0.00-1180.90] mg/g vs 4.73 [0.00-275.00] mg/g, respectively; P = 0.001). The ACR of obese women was higher than in normal weight subjects during the third trimester (16.79 mg/g [0.01-1180.90] vs 8.07 mg/g [0.10-402.14] respectively; adjusted P = 0.015). Both ACR change and third trimester ACR were weakly but significantly correlated with basal BMI (r: 0.228 P: 0.003 and r: 0.301 P < 0.001, respectively) but not with GWG or GWG rate. Basal BMI was not associated with first-trimester ACR. CONCLUSION: Obesity is associated with an increase in urinary albumin excretion during the course of pregnancy. Distinction of this relationship during pregnancy offers an opportunity for further research on pathophysiological mechanisms. The alarmingly high rate of non-compliance with IOM guidelines in pregnant women is a concern. Prompt measures for counseling of women before and during pregnancy in order to maintain healthy weight are needed.


Subject(s)
Albumins/analysis , Body Mass Index , Creatinine/urine , Overweight/urine , Pregnancy Complications/urine , Weight Gain/physiology , Adult , Female , Humans , Obesity/urine , Pregnancy
20.
Ren Fail ; 40(1): 416-422, 2018 Nov.
Article in English | MEDLINE | ID: mdl-30035656

ABSTRACT

AIM: The aim of this study was to examine the serum and urine levels of kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), osteopontin (OPN), matrix metalloproteinase-9 (MMP-9), and serum Cystatin-C to determine the renal effect of obesity in obese children. METHODS: Seventy-two obese and 35 non-obese healthy children were included in this study. Blood pressure (BP) was evaluated with office measurement. Creatinine, cystatin C, lipids, fasting glucose, and insulin levels were measured, and homeostasis model assessment -insulin resistance (HOMA-IR) was calculated. The urine albumin/creatinine ratio was calculated. The serum and urine KIM-1, NGAL, OPN, and MMP-9 levels were measured. RESULTS: Serum cystatin-C, triglyceride, and homeostasis model assessment-insulin resistance (HOMA-IR) index were found to be significantly higher in the obese group (p = .0001), and high-density lipoprotein (HDL) cholesterol was found to be significantly lower (p = .019) in the obese group. No significant differences were found in serum KIM-1, NGAL, OPN or MMP-9 levels between groups (p > .05). No significant differences were found in urine KIM-1 and MMP-9 levels (p > .05), Urine NGAL, and OPN levels were found significantly higher in obese groups (p < .05). CONCLUSIONS: According to our results, although serum KIM-1, NGAL, OPN, MMP-9, and urine MMP-9, urine KIM-1 do not appear to be ideal markers to evaluate renal injury in the early period of obesity, the serum levels of cystatin C and urine NGAL, urine OPN can be used as a good marker for assessing the renal effect of obesity which can lead end stage renal disease in pediatric population.


Subject(s)
Cystatin C/blood , Lipocalin-2/urine , Obesity/complications , Osteopontin/urine , Renal Insufficiency/diagnosis , Biomarkers/blood , Biomarkers/urine , Child , Creatinine/blood , Creatinine/urine , Cystatin C/urine , Female , Hepatitis A Virus Cellular Receptor 1/blood , Humans , Kidney , Kidney Function Tests , Lipocalin-2/blood , Male , Matrix Metalloproteinase 9/blood , Matrix Metalloproteinase 9/urine , Obesity/blood , Obesity/urine , Osteopontin/blood , Renal Insufficiency/blood , Renal Insufficiency/etiology , Renal Insufficiency/urine , Reproducibility of Results
SELECTION OF CITATIONS
SEARCH DETAIL